GENinCode Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 46

Employees

  • Stock Symbol
  • GENI

Stock Symbol

  • Investments
  • 3

GENinCode General Information

Description

GENinCode PLC principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes. The company has one operating segment. The company has presence in Spain, UK, United States, Italy, Germany, and Rest of World. The company generates majority of revenue from Spain. Its commercial products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode.

Contact Information

Website
www.genincode.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Oxford Science Park
  • John Eccles House, Robert Robinson Avenue
  • Oxford OX4 4GP
  • England, United Kingdom
+44 01865
Primary Industry
Biotechnology
Stock Exchange
LON
Vertical(s)
Digital Health, Life Sciences
Corporate Office
  • Oxford Science Park
  • John Eccles House, Robert Robinson Avenue
  • Oxford OX4 4GP
  • England, United Kingdom
+44 01865

GENinCode Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GENinCode Stock Performance

As of 13-Nov-2026, GENinCode’s current market cap is $5.98M with 753M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.98M 753M 2.68M -$0.02

GENinCode Financials Summary

As of 30-Jun-2026, GENinCode has a trailing 12-month revenue of $3.49M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 8,289 6,158 5,060 186
Revenue 3,487 4,052 3,451 2,685
EBITDA (7,108) (7,412) (6,115) (8,450)
Net Income (7,059) (7,515) (5,665) (8,721)
Total Assets 4,674 3,201 3,341 5,333
Total Debt 130 197 294 381
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GENinCode Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GENinCode‘s full profile, request access.

Request a free trial

GENinCode Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore GENinCode‘s full profile, request access.

Request a free trial

GENinCode Patents

  • 35

    Total Documents Applications and Grants

  • Total Patents Families

  • 19

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

GENinCode Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4194568-A1 Covid-19-associated venous thromboembolism Inactive 10-Dec-2021
WO-2023104840-A1 Covid-19-associated venous thromboembolism Inactive 10-Dec-2021
EP-4134450-A1 Prediction of cancer-associated venous thromboembolism Inactive 13-Aug-2021
WO-2023017135-A1 Prediction of cancer-associated venous thromboembolism Inactive 13-Aug-2021
US-20220380849-A1 Thromboembolic disease Inactive 25-May-2021 G16B20/20
To view GENinCode’s complete patent history, request access »

GENinCode Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GENinCode Acquisitions (3)

GENinCode’s most recent deal was a Merger/Acquisition with ROCA Test for . The deal was made on 27-Sep-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ROCA Test 27-Sep-2022 Merger/Acquisition Diagnostic Equipment
Ferrer inCode 22-Jul-2021 Merger/Acquisition Other Healthcare Services
GendiAG 12-Sep-2018 Merger/Acquisition Biotechnology
To view GENinCode’s complete acquisitions history, request access »

GENinCode ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Software & Services

Industry

Rank

Percentile

Enterprise and Infrastructure Software

Subindustry

Rank

Percentile

To view GENinCode’s complete esg history, request access »

GENinCode Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
ROCA Test Cambridge, United Kingdom 2010
GendiAG Barcelona, Spain 2006

GENinCode FAQs

  • When was GENinCode founded?

    GENinCode was founded in 2018.

  • Where is GENinCode headquartered?

    GENinCode is headquartered in Oxford, United Kingdom.

  • What is the size of GENinCode?

    GENinCode has 46 total employees.

  • What industry is GENinCode in?

    GENinCode’s primary industry is Biotechnology.

  • Is GENinCode a private or public company?

    GENinCode is a Public company.

  • What is GENinCode’s stock symbol?

    The ticker symbol for GENinCode is GENI.

  • What is the current market cap of GENinCode?

    The current market capitalization of GENinCode is $5.98M.

  • What is GENinCode’s current revenue?

    The trailing twelve month revenue for GENinCode is $3.49M.

  • What is GENinCode’s annual earnings per share (EPS)?

    GENinCode’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process